title: Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors.
abstract: The therapeutic potential of nanoparticle-based drug carriers depends largely on their ability to evade the host immune system while delivering their cargo safely to the site of action. Of particular interest are simple strategies for the functionalization of nanoparticle surfaces that are both inherently safe and can also bestow immunoevasive properties, allowing for extended blood circulation times. Here, we evaluated a recently reported cell membrane-coated nanoparticle platform as a drug delivery vehicle for the treatment of a murine model of lymphoma. These biomimetic nanoparticles, consisting of a biodegradable polymeric material cloaked with natural red blood cell membrane, were shown to efficiently deliver a model chemotherapeutic, doxorubicin, to solid tumor sites for significantly increased tumor growth inhibition compared with conventional free drug treatment. Importantly, the nanoparticles also showed excellent immunocompatibility as well as an advantageous safety profile compared with the free drug, making them attractive for potential translation. This study demonstrates the promise of using a biomembrane-coating approach as the basis for the design of functional, safe, and immunocompatible nanocarriers for cancer drug delivery.
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Luk
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Ronnie H
authors.initials: RH
authors.lastname: Fang
authors.affiliation: 2. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
authors.forename: Che-Ming J
authors.initials: CM
authors.lastname: Hu
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Copp
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Soracha
authors.initials: S
authors.lastname: Thamphiwatana
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Diana
authors.initials: D
authors.lastname: Dehaini
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Gao
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.; 3. Shiley Eye Institute, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Kang
authors.initials: K
authors.lastname: Zhang
authors.affiliation: 4. Department of Pediatric Research, MD Anderson Cancer Center, Houston, TX 77030, U.S.A.
authors.forename: Shulin
authors.initials: S
authors.lastname: Li
authors.affiliation: 1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
authors.forename: Liangfang
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage* / Q000494:pharmacology; D004337:Drug Carriers / Q000378:metabolism*; D004910:Erythrocyte Membrane / Q000737:chemistry*; D064593:Heterografts; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008810:Mice, Inbred C57BL; D049329:Nanostructures; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D004317:Doxorubicin
keywords: biomimetic nanoparticle; drug delivery; immunocompatible nanocarrier; lymphoma treatment.; nanomedicine